

## Pooled data from DURATION 1 & 5: All treatment emergent adverse events with frequency of $\geq 5\%$

Preferred Term	Exenatide QW (N=277) n (%)	Exenatide BID (N=268) n (%)
Nausea	58 (20.9)	93 (34.7)
Diarrhoea	34 (12.3)	24 (9.0)
Injection Site Pruritis	33 (11.9)	3 (1.1)
Vomiting	22 (7.9)	38 (14.2)
Upper respiratory tract infection	21 (7.6)	30 (11.2)
Urinary tract infection	19 (6.9)	16 (6.0)
Injection-site erythema	18 (6.5)	3 (1.1)
Constipation	17 (6.1)	14 (5.2)
Headache	15 (5.4)	17 (6.3)
Gastroenteritis viral	15 (5.4)	8 (3.0)
Dyspepsia	15 (5.4)	6 (2.2)
Nasopharyngitis	15 (5.4)	9 (3.4)
Injection-site hematoma	13 (4.7)	22 (8.2)
Dizziness	8 (2.9)	17 (6.3)